Ocugen Details Positive OCU410 Phase 2 Data & Comprehensive Gene Therapy Pipeline in Investor Presentation
OCGN has more than doubled off its 52-week low of $0.57.
Summary
Ocugen filed an 8-K with a detailed investor presentation, confirming positive Phase 2 data for OCU410 in Geographic Atrophy and outlining its gene therapy pipeline's progress and BLA timelines.
Key Events · Product Development and Regulatory · OCGN
-
Detailed OCU410 Phase 2 Data
The presentation provides comprehensive 12-month Phase 2 data for OCU410 in Geographic Atrophy, showing a 31% reduction in lesion size and 27% slower Ellipsoid Zone (EZ) loss with the optimal dose. Additionally, 55% of participants achieved a ≥30% reduction in lesion size.
-
Pipeline Advancement & BLA Timelines
Updates on the gene therapy pipeline include OCU400 (Retinitis Pigmentosa) with Phase 3 enrollment completed and BLA submission targeted for 2026, and OCU410ST (Stargardt Disease) with pivotal Phase 2/3 initiated and BLA submission targeted for 2027.
-
OCU410 Phase 3 Initiation
Ocugen plans to initiate a global Phase 3 trial for OCU410 in Geographic Atrophy in Q3 2026, targeting BLA submission in 2028.
Analysis · OCGN · Life Sciences
This 8-K furnishes a detailed investor presentation outlining significant advancements across Ocugen's gene therapy pipeline. The presentation provides comprehensive data for the recently announced positive 12-month Phase 2 results for OCU410 in Geographic Atrophy, showing a 31% reduction in lesion size and 27% slower EZ loss with the optimal dose. It also updates on the progress of OCU400 for Retinitis Pigmentosa (Phase 3 enrollment completed, BLA submission targeted 2026) and OCU410ST for Stargardt Disease (pivotal Phase 2/3 initiated, BLA submission targeted 2027). This detailed disclosure reinforces the company's clinical progress and provides a clear roadmap for its lead programs, substantiating the positive news from March 24th.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OCGN was trading at $1.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $642.7M. The 52-week trading range was $0.57 to $2.73. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.